Poll: How Much Discretion Should Payers Have Over Biosimilar Coverage?

Coverage policies for biosimilars in the health care industry are the source of much angst.

How extensive should payer coverage of biosimilars be?

All biosimilars and reference products
Just reference products
Just biosimilars
Just the biosimilars and/or reference products the payer wants to cover
Related Videos
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Michael Kleinrock
Ian Henshaw
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
Ryan Haumschild, PharmD
Ryan Haumschild, PharmD
Julie M. Reed
Eric Tichy, PharmD, MBA
Julie M. Reed
Related Content
© 2023 MJH Life Sciences

All rights reserved.